Cargando…
Polygenic risk score across distinct colorectal cancer screening outcomes: from premalignant polyps to colorectal cancer
BACKGROUND: Different risk-based colorectal cancer (CRC) screening strategies, such as the use of polygenic risk scores (PRS), have been evaluated to improve effectiveness of these programs. However, few studies have previously assessed its usefulness in a fecal immunochemical test (FIT)-based scree...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8574048/ https://www.ncbi.nlm.nih.gov/pubmed/34743725 http://dx.doi.org/10.1186/s12916-021-02134-x |
_version_ | 1784595541892530176 |
---|---|
author | Obón-Santacana, Mireia Díez-Villanueva, Anna Alonso, Maria Henar Ibáñez-Sanz, Gemma Guinó, Elisabet López, Ana Rodríguez-Alonso, Lorena Mata, Alfredo García-Rodríguez, Ana Palomo, Andrés García Molina, Antonio J. Garcia, Montse Binefa, Gemma Martín, Vicente Moreno, Victor |
author_facet | Obón-Santacana, Mireia Díez-Villanueva, Anna Alonso, Maria Henar Ibáñez-Sanz, Gemma Guinó, Elisabet López, Ana Rodríguez-Alonso, Lorena Mata, Alfredo García-Rodríguez, Ana Palomo, Andrés García Molina, Antonio J. Garcia, Montse Binefa, Gemma Martín, Vicente Moreno, Victor |
author_sort | Obón-Santacana, Mireia |
collection | PubMed |
description | BACKGROUND: Different risk-based colorectal cancer (CRC) screening strategies, such as the use of polygenic risk scores (PRS), have been evaluated to improve effectiveness of these programs. However, few studies have previously assessed its usefulness in a fecal immunochemical test (FIT)-based screening study. METHODS: A PRS of 133 single nucleotide polymorphisms was assessed for 3619 participants: population controls, screening controls, low-risk lesions (LRL), intermediate-risk (IRL), high-risk (HRL), CRC screening program cases, and clinically diagnosed CRC cases. The PRS was compared between the subset of cases (n = 648; IRL+HRL+CRC) and controls (n = 956; controls+LRL) recruited within a FIT-based screening program. Positive predictive values (PPV), negative predictive values (NPV), and the area under the receiver operating characteristic curve (aROC) were estimated using cross-validation. RESULTS: The overall PRS range was 110–156. PRS values increased along the CRC tumorigenesis pathway (Mann-Kendall P value 0.007). Within the screening subset, the PRS ranged 110-151 and was associated with higher risk-lesions and CRC risk (OR(D10vsD1) 1.92, 95% CI 1.22–3.03). The cross-validated aROC of the PRS for cases and controls was 0.56 (95% CI 0.53–0.59). Discrimination was equal when restricted to positive FIT (aROC 0.56), but lower among negative FIT (aROC 0.55). The overall PPV among positive FIT was 0.48. PPV were dependent on the number of risk alleles for positive FIT (PPVp10-p90 0.48–0.57). CONCLUSIONS: PRS plays an important role along the CRC tumorigenesis pathway; however, in practice, its utility to stratify the general population or as a second test after a FIT positive result is still doubtful. Currently, PRS is not able to safely stratify the general population since the improvement on PPV values is scarce. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-021-02134-x. |
format | Online Article Text |
id | pubmed-8574048 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-85740482021-11-08 Polygenic risk score across distinct colorectal cancer screening outcomes: from premalignant polyps to colorectal cancer Obón-Santacana, Mireia Díez-Villanueva, Anna Alonso, Maria Henar Ibáñez-Sanz, Gemma Guinó, Elisabet López, Ana Rodríguez-Alonso, Lorena Mata, Alfredo García-Rodríguez, Ana Palomo, Andrés García Molina, Antonio J. Garcia, Montse Binefa, Gemma Martín, Vicente Moreno, Victor BMC Med Research Article BACKGROUND: Different risk-based colorectal cancer (CRC) screening strategies, such as the use of polygenic risk scores (PRS), have been evaluated to improve effectiveness of these programs. However, few studies have previously assessed its usefulness in a fecal immunochemical test (FIT)-based screening study. METHODS: A PRS of 133 single nucleotide polymorphisms was assessed for 3619 participants: population controls, screening controls, low-risk lesions (LRL), intermediate-risk (IRL), high-risk (HRL), CRC screening program cases, and clinically diagnosed CRC cases. The PRS was compared between the subset of cases (n = 648; IRL+HRL+CRC) and controls (n = 956; controls+LRL) recruited within a FIT-based screening program. Positive predictive values (PPV), negative predictive values (NPV), and the area under the receiver operating characteristic curve (aROC) were estimated using cross-validation. RESULTS: The overall PRS range was 110–156. PRS values increased along the CRC tumorigenesis pathway (Mann-Kendall P value 0.007). Within the screening subset, the PRS ranged 110-151 and was associated with higher risk-lesions and CRC risk (OR(D10vsD1) 1.92, 95% CI 1.22–3.03). The cross-validated aROC of the PRS for cases and controls was 0.56 (95% CI 0.53–0.59). Discrimination was equal when restricted to positive FIT (aROC 0.56), but lower among negative FIT (aROC 0.55). The overall PPV among positive FIT was 0.48. PPV were dependent on the number of risk alleles for positive FIT (PPVp10-p90 0.48–0.57). CONCLUSIONS: PRS plays an important role along the CRC tumorigenesis pathway; however, in practice, its utility to stratify the general population or as a second test after a FIT positive result is still doubtful. Currently, PRS is not able to safely stratify the general population since the improvement on PPV values is scarce. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-021-02134-x. BioMed Central 2021-11-08 /pmc/articles/PMC8574048/ /pubmed/34743725 http://dx.doi.org/10.1186/s12916-021-02134-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Obón-Santacana, Mireia Díez-Villanueva, Anna Alonso, Maria Henar Ibáñez-Sanz, Gemma Guinó, Elisabet López, Ana Rodríguez-Alonso, Lorena Mata, Alfredo García-Rodríguez, Ana Palomo, Andrés García Molina, Antonio J. Garcia, Montse Binefa, Gemma Martín, Vicente Moreno, Victor Polygenic risk score across distinct colorectal cancer screening outcomes: from premalignant polyps to colorectal cancer |
title | Polygenic risk score across distinct colorectal cancer screening outcomes: from premalignant polyps to colorectal cancer |
title_full | Polygenic risk score across distinct colorectal cancer screening outcomes: from premalignant polyps to colorectal cancer |
title_fullStr | Polygenic risk score across distinct colorectal cancer screening outcomes: from premalignant polyps to colorectal cancer |
title_full_unstemmed | Polygenic risk score across distinct colorectal cancer screening outcomes: from premalignant polyps to colorectal cancer |
title_short | Polygenic risk score across distinct colorectal cancer screening outcomes: from premalignant polyps to colorectal cancer |
title_sort | polygenic risk score across distinct colorectal cancer screening outcomes: from premalignant polyps to colorectal cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8574048/ https://www.ncbi.nlm.nih.gov/pubmed/34743725 http://dx.doi.org/10.1186/s12916-021-02134-x |
work_keys_str_mv | AT obonsantacanamireia polygenicriskscoreacrossdistinctcolorectalcancerscreeningoutcomesfrompremalignantpolypstocolorectalcancer AT diezvillanuevaanna polygenicriskscoreacrossdistinctcolorectalcancerscreeningoutcomesfrompremalignantpolypstocolorectalcancer AT alonsomariahenar polygenicriskscoreacrossdistinctcolorectalcancerscreeningoutcomesfrompremalignantpolypstocolorectalcancer AT ibanezsanzgemma polygenicriskscoreacrossdistinctcolorectalcancerscreeningoutcomesfrompremalignantpolypstocolorectalcancer AT guinoelisabet polygenicriskscoreacrossdistinctcolorectalcancerscreeningoutcomesfrompremalignantpolypstocolorectalcancer AT lopezana polygenicriskscoreacrossdistinctcolorectalcancerscreeningoutcomesfrompremalignantpolypstocolorectalcancer AT rodriguezalonsolorena polygenicriskscoreacrossdistinctcolorectalcancerscreeningoutcomesfrompremalignantpolypstocolorectalcancer AT mataalfredo polygenicriskscoreacrossdistinctcolorectalcancerscreeningoutcomesfrompremalignantpolypstocolorectalcancer AT garciarodriguezana polygenicriskscoreacrossdistinctcolorectalcancerscreeningoutcomesfrompremalignantpolypstocolorectalcancer AT palomoandresgarcia polygenicriskscoreacrossdistinctcolorectalcancerscreeningoutcomesfrompremalignantpolypstocolorectalcancer AT molinaantonioj polygenicriskscoreacrossdistinctcolorectalcancerscreeningoutcomesfrompremalignantpolypstocolorectalcancer AT garciamontse polygenicriskscoreacrossdistinctcolorectalcancerscreeningoutcomesfrompremalignantpolypstocolorectalcancer AT binefagemma polygenicriskscoreacrossdistinctcolorectalcancerscreeningoutcomesfrompremalignantpolypstocolorectalcancer AT martinvicente polygenicriskscoreacrossdistinctcolorectalcancerscreeningoutcomesfrompremalignantpolypstocolorectalcancer AT morenovictor polygenicriskscoreacrossdistinctcolorectalcancerscreeningoutcomesfrompremalignantpolypstocolorectalcancer |